Tenderwize
Wróć do wyszukiwania

Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2028 · 675 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...

Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Open House conclusion of pharmaceutical discount agreements under Section 130a(8) SGB V for Epoetin alfa and Epoetin zeta.
  • Nationwide supply/performance in Germany.
Pokaż pełne podsumowanie

Open House procedure by Techniker Krankenkasse for non-exclusive discount agreements on pharmaceutical products for Epoetin alfa and Epoetin zeta (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with uniform conditions and no individual negotiation. The contract term is up to 24 months from 01/07/2026 to 30/06/2028. No contract value is stated in the provided data. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the procedure communication is via the TK portal communication area/email. Procurement documents are available online, but only the notice text was provided for analysis.

Ryzyka

The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...

Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the relevant medicines.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the medicines and/or otherwise be entitled to place them on the market in its own name.

Kryteria udzielenia

Lot 1

Open House notice field only; award criteria not materially applicable.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta

Lot 1 concerns an Open House discount agreement for the medicinal products Epoetin alfa and Epoetin zeta. Scope is nationwide in Germany. The notice indicates open accession for all eligible pharmaceutical companies, no exclusivity, and no individual negotiation. The lot details come from structured data and notice text.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jun 2026 - Jun 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

Open House notice field only; award criteria not materially applicable.

Termin

Deadline Jun 30, 2028

Szczegóły zamówienia

Data publikacji
07 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
317941-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3